Teva, Par Win Patent Appeal on Pronova Heart Drug in U.S.
This article is for subscribers only.
Teva Pharmaceuticals USA Inc. and Par Pharmaceutical Cos. won an appeal in their bid to sell a generic version of BASF SE’s heart medicine Lovaza in the U.S.
The U.S. Court of Appeals for the Federal Circuit in a ruling today said it reversed a lower court decision because one patent held by BASF’s Pronova unit had been made publicly accessible and another had expired.